Share This Page
Patent: 9,169,212
✉ Email this page to a colleague
Summary for Patent: 9,169,212
| Title: | Azepane derivatives and methods of treating hepatitis B infections | |||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject. | |||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Hartman; George D. (Lansdale, PA), Kuduk; Scott (Harleysville, PA) | |||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Novira Therapeutics, Inc. (Doylestown, PA) | |||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | 14/511,964 | |||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | |||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | United States Patent 9,169,212 (HBV): What the Claims Actually Cover and Where the Landscape LeaksWhat is US 9,169,212 claiming at the compound level?US 9,169,212 is structured as a classic HBV “compound + composition + treatment method” patent. The key constraint is that the scope of the core inventive subject matter is limited to a specific set of enumerated compounds (Claim 1) and then to a set of enumerated structural formula embodiments (Claims 13 to 20). The method claims (Claims 3 to 12) then fold in broad combination-therapy language that does not itself create a novel compound, but can materially extend enforcement leverage depending on what the compound in Claim 1 is and how it is used clinically. Claim set (high-level)
Critical implicationIf the compound set in Claim 1 is narrow, the overall patent family’s practical value is driven by:
1) whether the enumerated compounds are potent against HBV viral processes in humans at relevant doses, and The dependent method claims broaden the potential clinical use, but they do not expand beyond the Claim 1 compound being used. How broad are the method claims for combination therapy?Claims 4 through 12 impose the most enforcement-relevant expansion beyond “treat HBV with compound X.” Combination therapy language is wide, but only as dependent claimsClaim 4: method of Claim 3 further comprising at least one additional therapeutic agent selected from a long list that includes (verbatim from your excerpt):
This is structurally important: it is a Markush list that allows “at least one” agent from a wide set. Specifics that meaningfully narrow dependent scopeClaims 5 to 10 narrow the “additional agent” to particular agent classes and then to explicit named compounds: Reverse transcriptase inhibitor branch (Claim 5) Includes nucleos(t)ide analogs such as: Zidovudine, Didanosine, Zalcitabine, dideoxyadenosine (2’,3’-dideoxyadenosine), Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, cidofovir, Efavirenz, Nevirapine, Delavirdine, Etravirine. TLR agonist branch (Claim 6) Only two explicit examples:
Interferon branch (Claims 7-10)
Critical implication for enforcement strategy
From a competitive standpoint, a company can often:
Where does design-around pressure realistically sit?1) Claim 1 compound enumeration is the gating elementClaims 2 and 3 are directly dependent on Claim 1. If the competitor avoids using the exact enumerated compound(s) (or their pharmaceutically acceptable salts), Claim 2-3 fall away. 2) Dependent regimens can be engineered to avoid certain narrow recitationsThe most “actionable” design-around points are:
However, Claim 4 still captures “immunomodulatory agents” and “pegylated interferon” broadly. So avoiding only Claim 10 may not remove exposure under Claim 4, depending on the exact therapy. 3) Salt forms and pharmaceutically acceptable saltsClaims explicitly cover “a pharmaceutically acceptable salt thereof.” This typically makes salt-based design-arounds harder unless the competitor uses:
Without the exact chemical identities shown in your Markush blocks, the strength of salt coverage cannot be fully stress-tested from your excerpt alone. What does Claims 13 to 20 add beyond Claim 1?Claims 13-20 recite “structural formula” embodiments that are each “or a pharmaceutically acceptable salt thereof,” tied back to Claim 1. Critical implicationIn many HBV compound patents, these structural claims do three things:
Your excerpt shows Claim 13-20 as distinct structural formulas, but the chemical structures themselves are embedded in your text as placeholders (##STR00740## etc.). That means the precise overlap with known chemical space cannot be compared here. How does the combination-therapy claim set interact with HBV standard of care?The dependent list in Claim 4 spans major HBV therapeutic modality categories (polymerase inhibitors, interferons, viral entry inhibitors, capsid assembly modulators, vaccines, and immunomodulators). That breadth matters because it increases the chance that at least one widely used regimen could land inside the claim scope. Key practical outcomes:
But again: enforceability hinges on the accused product administering Claim 1 compound and on the additional agents matching dependent selections if the patentee asserts dependents. Patent landscape risks: what kinds of prior art typically attack this claim structureUS HBV compound patents usually face the same validity pressure points. US 9,169,212’s claim architecture suggests it is particularly vulnerable if the enumerated compounds map closely to known HBV-related scaffolds. Likely validity attack vectors (by claim type)
Critical observation on combination claimsCombination therapy claims that list broad classes without requiring a specific dosing schedule, sequence, or mechanistic interaction are commonly attacked as “routine combination” if the prior art suggests combining those modalities in HBV generally. Claim 4 is broad on purpose. That breadth increases coverage but also increases vulnerability on obviousness. Freedom-to-operate (FTO): what matters operationallyFrom an FTO perspective, you should treat US 9,169,212 as two layers of risk: 1) Compound risk (highest): does the candidate drug contain or release a Claim 1 compound in vivo in a manner that satisfies “administering a therapeutically effective amount of a compound of claim 1”? Regimen risk matrix (based on your excerpt)
Key Takeaways
FAQs1) Does US 9,169,212 primarily cover a compound, or a treatment regimen?It primarily covers a specific set of compounds (Claim 1) and then extends to HBV treatment methods (Claim 3) using those compounds, with broader combination regimens in dependent claims (Claim 4). 2) What is the biggest design-around lever?Avoiding administration of the exact Claim 1 enumerated compound(s) (or their pharmaceutically acceptable salts) is the strongest lever because Claims 2-3 depend on Claim 1. 3) Are combination therapy claims broad enough to cover most HBV standard-of-care?Claim 4 is broad across many HBV modality categories (polymerase inhibitors, interferons, viral entry, capsid modulators, vaccines). Whether a specific regimen fits depends on the exact additional agent(s), with narrower dependents for some selections. 4) Which dependent claims are most specific and easiest to engineer around?Claim 6 (only SM360320 and AZD 8848) and Claim 10 (PEGASYS) are the most specific. If those agents are excluded, dependent-claim overlap can drop. 5) What drives infringement risk if a competitor uses the same compound but different HBV combinations?Claim 3 can still be implicated if the competitor uses the Claim 1 compound for HBV, while dependent combination claims (4-12) turn on whether the added agent choices match the recited selections. References[1] United States Patent No. 9,169,212. More… ↓ |
